Detalles de la búsqueda
1.
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
Ann Rheum Dis
; 83(2): 199-213, 2024 Jan 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37793792
2.
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
Ann Rheum Dis
; 82(4): 515-526, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36649967
3.
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.
RMD Open
; 10(2)2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38834351
4.
Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension Study.
ACR Open Rheumatol
; 4(9): 819-824, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35833532
5.
Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Arthritis Rheumatol
; 74(12): 1943-1958, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35829672
Resultados
1 -
5
de 5
1
Próxima >
>>